Bydureon (AstraZeneca) 2017-2018 U.S. Promotional Audit Report - ResearchAndMarkets.com

September 24, 2018

DUBLIN--(BUSINESS WIRE)--Sep 24, 2018--The “Bydureon 2017 U.S. Promotional Audit Report” report has been added to ResearchAndMarkets.com’s offering. The 5 Key Questions Addressed

How many physicians were reached by Bydureon through reportable promotional activity in 2017 and how does this compare to its peer set in the Type 2 Diabetes - GLP1 market? What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity? How does AstraZeneca’s depth of coverage vary within key specialties (e.g., Family Medicine, Internal Medicine, Endocrinology, and General Practice) and how does this compare to its peers and the overall set of rep-accessible physicians? How often are physicians receiving paid meals for Bydureon throughout the year (e.g., monthly, quarterly, annually)? Who were the most frequent meal recipients and top paid speakers for Bydureon in 2017?

Data Sources & Methodology

The author leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than four years of longitudinal data is available - covering payments to more than 975,000 U.S. healthcare professionals. Over 13,600 paid interactions across 7,300 physicians made on behalf of Bydureon were carefully examined to support our analysis.

For more information about this report visit https://www.researchandmarkets.com/research/3lwf67/bydureon?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180924005423/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/24/2018 06:47 AM/DISC: 09/24/2018 06:47 AM


Update hourly